Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
 
 
 

New business opportunities in the U.S.

„As a key provider to the digital industry, we already have good ties to technology companies in Silicon Valley. Over the past two weeks, we have expanded our presence here and in other parts of the U.S. by entering into new partnerships and pursuing further business opportunities.“
Stefan Oschmann, Chairman of the Executive Board and CEO 

 

Our company seals collaborations in Silicon Valley

By collaborating with U.S. software developer Palantir Technologies of Palo Alto, California and the Stanford Graduate School of Business and entering into three further agreements with U.S. partners, we are opening up new business opportunities and strengthening its position as an innovation-based science and technology company.  

The partnership with Palantir allows our company to use Palantir’s advanced data analytics capabilities to more rapidly develop and deliver medicines and commercialize new products to achieve better patient outcomes. Initially we will apply Palantir’s technology to cancer treatment, particularly in the following areas: the development of a collaborative data and analytics platform for high-precision drug development processes, the analysis of data to better understand therapeutic efficacy, and the creation of a platform for better global supply chain forecasting.  
By cooperating with the Stanford Graduate School of Business (Stanford GSB), our company is adding a new module on innovation and digitalization to the curriculum of its internal company university.  Our executives will receive advanced training in these subject areas through lectures and practical lessons with teaching staff from Stanford GSB.

The partnerships were officially sealed in January 2017 during a visit by our Executive Board to Silicon Valley. Likewise in January, we signed a licensing agreement with Vertex Pharmaceuticals (Boston) to develop new approaches in cancer therapy, entered into a collaboration agreement with the University of Texas MD Anderson Cancer Center (Houston) covering the use of a research platform, and acquired BioControl Systems (Seattle), a global leader in food safety testing. 

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.
 

CONTACT

Gangolf Schrimpf
GANGOLF SCHRIMPF
Healthcare
Tel: +49 6151 72-9591
Fax: +49 6151 72-919591
Merck KGaA, Darmstadt, Germany on Facebook
Merck KGaA, Darmstadt, Germany on LinkedIn
Twitter
Merck on Slideshare